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OBJECTIVES The purpose of this study was to develop 30-day and 1-year risk stratification models for
non–ST-segment elevation acute coronary syndrome (NSTE-ACS) patients that incorporate
quantitative ST-segment depression and novel biomarkers.
BACKGROUND Several novel biomarkers have changed the risk profile of ACS; thus, the reassessment of
traditional indicators such as ST-segment depression in this new context is warranted.
METHODS Multivariable logistic regression was used to identify significant predictors of 30-day death
and death/myocardial infarction (MI) and 1-year mortality in 7,800 NSTE-ACS patients
enrolled in the GUSTO-IV (Global Utilization of Strategies to Open Occluded Arteries-IV
ACS) trial between 1998 and 2000.
RESULTS Among all other predictors, the degree of ST-segment depression had the highest prognostic
value for 30-day death, 30-day death/MI, and 1-year death. Troponin T (TnT), creatinine
clearance, N-terminal pro-brain natriuretic peptide (NT-proBNP), heart rate, and age were
also highly influential on adverse outcomes. Unlike TnT and NT-proBNP, C-reactive
protein was only predictive of long-term death. In contrast to mortality, the contribution of
TnT to predicting 30-day death/MI increased, whereas NT-proBNP’s role was attenuated.
The discriminatory power was excellent (c-index [adjusted for over-optimism]: 0.82 [30-day
death]; 0.72 [30-day death/MI]; 0.81 [1-year]).
CONCLUSIONS In this large contemporary study of NSTE-ACS patients, novel insights into risk stratifica-
tion were observed—in particular, the utility of quantitative ST-segment depression and
multiple biomarkers. Collection of these indicators in future NSTE-ACS populations is
recommended to evaluate generalizability and clinical application of these findings. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.085Coll Cardiol 2006;48:939–47) © 2006 by the American College of Cardiology Foundation
s
c
v
b
c
s
p
t
a
t
O
t
s
d
M
S
t
o
w

lemographics, comorbidities, and other classic patient
actors have long been the foundation of risk stratification in
cute coronary syndromes (ACS) (1–4). More recently,
everal biomarkers have also been shown to be associated
ith the risk for subsequent coronary events, including
ndicators of myocardial necrosis (troponin), inflammation
C-reactive protein), and hemodynamic stress (brain natri-
retic peptides).
The electrocardiogram (ECG) has continually played an
mportant role in prognosis of ACS patients. ST-segment
epression 0.5 mm at baseline, for instance, is associated
ith poorer prognosis than absence of ST-segment depres-
ion. The extent of ST-segment depression, however, is
arely measured or reported even though this refinement
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nterpretation of the data, manuscript preparation, review or approval, or the decision
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Manuscript received January 1, 2006; revised manuscript received March 28, 2006,
ccepted April 24, 2006.ubstantially improves risk stratification compared with
onventional qualitative ECG data (5–8). The prognostic
alue of combining quantitative ECG data and the extended
iomarker profile with classical patient risk factors is un-
lear. Thus, the systematic collection of quantitative ST-
egment depression, cardiac troponin T (TnT), C-reactive
rotein (CRP), and N-terminal pro-brain natriuretic pep-
ide (NT-proBNP) in 7,800 non–ST-segment elevation
cute coronary syndrome (NSTE-ACS) patients enrolled in
he GUSTO-IV (Global Utilization of Strategies to Open
ccluded Arteries-IV ACS) trial provided a unique oppor-
unity to investigate the relative roles of factors influencing
hort- and long-term outcomes (9). Risk scores were also
eveloped to illustrate potential clinical applications.
ETHODS
tudy population. The details of the GUSTO-IV-ACS
rial have been previously described (9,10). Briefly, patients
ver the age of 21 years were eligible if they presented
ithin 24 h after an episode of ischemic chest pain lasting
5 min and had either elevated TnT/TnI above the upper
imit of normal (ULN) according to the local quantitative or
ualitative assays or transient/persistent ST-segment de-
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Value-Added Risk Stratification in ACS September 5, 2006:939–47ression (0.5 mm) that was not known to be pre-existing
nd not attributable to a co-existing disorder or medication
n the admission ECG.
Patients were randomly assigned to abciximab (0.25
g/kg bolus plus 0.125 g/kg/min infusion for 24 or 48 h)
r placebo. Because abciximab did not reduce the primary or
econdary end points, patients from all 3 treatment arms
ere combined for this analysis. Coronary angiography was
ot to be performed during or within 12 h after the
ompletion of the study agent infusion. Patients also re-
eived aspirin and either unfractionated or low-molecular-
eight heparin. Other clinically indicated medications were
sed at the discretion of the treating physician.
CG analysis. Standard 12-lead baseline ECG data ob-
ained at baseline were centrally evaluated by 2 experienced
eaders without knowledge of the clinical outcomes in 7,741
atients (99.2%) at the ECG core laboratory (Cleveland
linic Foundation, Cleveland, Ohio) and were entered and
nalyzed at the Canadian VIGOUR Centre (University of
lberta, Edmonton, Canada). ST-segment depression was
rospectively defined and measured with the aid of a
agnifying caliper to the nearest 0.5 mm in all leads except
VR. ST-segment depression was judged to be present if the
point was depressed by 0.5 mm and was followed by a
orizontal or down-sloping ST-segment for at least 0.08 s.
atients were classified as having ST-segment depression if
he ST-segment was depressed by0.5 mm in 2 of the limb
eads or at least 2 contiguous precordial leads. Patients were
ategorized into 5 mutually exclusive groups: no ST-
egment depression, 0.5-mm, 1- to 1.5-mm, 2-mm ST-
egment depression, and “confounders.” Confounders in-
luded left bundle branch block, paced rhythm or ventricular
hythm in 225 patients, or ST-segment elevation on the
aseline ECG in 289 patients.
iomarker analysis. Blood samples were drawn at baseline
nd analyzed at a core laboratory (Department of Clinical
hemistry, University of Uppsala, Uppsala, Sweden). De-
ails of the assays used have been previously published (11).
aseline levels of TnT, CRP, and NT-proBNP were
etermined per protocol in all but 685 (8.8%), 692 (8.9%),
nd 991 (12.7%) patients, respectively. The loss of 500
amples during transport accounts for much of these miss-
ng data. Complete data for all 3 biomarkers were available
n 6,809 (87.3%) patients.
Baseline serum creatinine concentration (mg/dl) was
easured at local laboratories in 7,703 of 7,800 patients. To
Abbreviations and Acronyms
CRP  C-reactive protein
ECG  electrocardiogram
NSTE-ACS  non–ST-segment elevation acute
coronary syndrome
NT-proBNP  N-terminal pro-brain natriuretic peptide
PCI  percutaneous coronary intervention
TnT  cardiac troponin Tssess renal function, creatinine clearance was calculated with the Cockcroft-Gault equation, which adjusts for age,
ender, and weight (12).
nd point definitions. The end points of the current study
ncluded 30-day death, 30-day death or MI, and 1-year
eath, as described previously (9). Double counting of
atients with more than 1 event was avoided by classifying
ach patient according to the event with the greatest
everity. Thus, a patient with MI who subsequently died
as classified as experiencing death but not MI. At 1 year
ost-randomization, follow-up data on vital status were
btained and were complete in 7,746 patients (99.3%).
ossible cases of MI were adjudicated by a clinical end point
ommittee that was not aware of biomarker levels evaluated
n the core laboratory (i.e., TnT, CRP, NT-proBNP) or the
xtent of ST-segment depression on the baseline ECG (9).
tatistical analysis. Baseline characteristics were summa-
ized by frequency and percentage for categorical variables
nd by median and interquartile range for continuous
ariables. Creatinine clearance, TnT, CRP, and NT-
roBNP were categorized into quartiles of their distribu-
ions for ease of presentation (11). The choice of TnT over
reatine kinase-MB as the preferred marker of myocardial
amage was based on established guidelines as well as by an
ndependent analysis of their relative prognostic power
Appendix 1) (13).
Logistic regression evaluated the associations between
aseline characteristics and adverse outcomes. Indicators
ere entered into the full multivariable model if the p value
f the univariable association was 0.25. The final multi-
ariable model was constructed by backward stepwise elim-
nation of the least significant factors and the Akaike
nformation criteria. Given that 1-year follow-up was com-
lete in 99.3% of patients, logistic regression was repeated
o determine predictors of 1-year mortality. Unadjusted and
djusted odds ratios and their corresponding 95% confi-
ence intervals are reported.
The Hosmer-Lemeshow goodness-of-fit test statistic and
alibration of the predicted versus observed event rate
ccording to deciles of predicted risk were calculated to
ssess model performance. The discriminatory power was
stimated by the c-index (i.e., probability of concordance
etween observed and predicted survival on the basis of pairs
f individuals). The models were developed in the entire
tudy population and validated by bootstrapping techniques:
00 bootstrap samples were drawn, with replacement, to
stimate the amount of “over-optimism” in the models on
he basis of the entire population and quantified by the
ecrease in the area under the receiver operating character-
stic curve (14).
Simplified risk scores were developed to demonstrate the
otential for clinical application. The top 5 contributing
actors in the model were assigned weights that were
quivalent to the logistic regression coefficient multiplied by
0. For patient “i”, a weighted risk score was estimated by
umming the weighted risk for each variable (risk score 
10ixi, where beta was the regression coefficient associated
ith the factor, and x was equal to 1 when the factor was
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September 5, 2006:939–47 Value-Added Risk Stratification in ACSresent and 0 when absent). The discriminatory power of
he simplified risk scores was also adjusted for over-
ptimism.
ESULTS
verall, 301 (3.9%) of the 7,800 enrolled patients died
ithin 30 days after randomization, with an additional 348
atients (4.5%) dying between 30 days and 1 year (Table 1).
f the 659 (8.4%) patients who had an MI or died within
0 days, 358 had a non-fatal MI, 74 had an MI and died,
nd 227 died without an MI. Patients who experienced an
nd point were more often older and had a higher frequency
f comorbidities and prior cardiac history. Baseline biomar-
ers (i.e., TnT, NT-proBNP, CRP), heart rate, and the
xtent of ST-segment depression were significantly higher
n patients who died within 30 days or 1 year.
redictors of 30-day death. Thirteen of 19 possible pre-
ictors of 30-day mortality remained statistically significant
n the final model. (Table 2). Compared with those without
T-segment depression, the likelihood of 30-day death was
wice as high in patients with 1- to 1.5-mm and nearly
-fold higher with 2-mm ST-segment depression, after
aseline adjustment (p  0.001). ST-segment depression
ontributed the most to the model, as indicated by the
ercentage of the total chi-square (Fig. 1). Creatinine
able 1. Baseline Characteristics According to Survival Status at
30-Day Death
Survived Died
7,499 301
ge, yrs* 66 (57–73) 74 (69–79)†
en, % 62.6 59.5
aucasian, % 96.8 96.3
ypertension, % 51.8 62.8†
istory of hyperlipidemic
therapy, %
35.0 39.2
iabetes mellitus, % 21.1 33.6†
urrent smoker, % 22.9 17.3‡
istory of angina pectoris, % 45.4 60.1†
istory of MI, % 30.9 50.5†
istory of heart failure, % 7.7 23.3†
istory of PCI, % 9.9 6.6
istory of CABG, % 9.2 8.6
istory of stroke, % 2.4 7.3†
ody weight, kg* 76 (68–86) 74 (64–83)†
eart rate, beats/min 68 (60–79) 75 (65–93)†
reatinine clearance, ml/min* 78 (59–99) 55 (39–72)†
T-segment depression, mm †
None 34.0 13.7
0.5 27.3 15.3
1.0–1.5 27.4 35.3
2 5.0 20.3
Confounders§ 6.3 15.3
roponin T, g/l* 0.11 (0.01–0.44) 0.41 (0.08–1.10)† 0
T-proBNP, ng/l* 635 (228–1,724) 2,926 (1,193–7,683)† 6
RP, mg/l* 3.90 (1.81–9.40) 6.76 (2.74–24.3)† 3
Median (interquartile range). †p  0.001 (died vs. survived). ‡p  0.05 (died vs. sur
r ST-segment elevation on the baseline electrocardiogram (ECG).
CABG coronary artery bypass graft; CRPC-reactive protein; MImyocardi
oronary intervention.learance was also strongly associated with 30-day mortality: patients with creatinine clearance 58.4 ml/min had a
-fold increase in the risk of 30-day death relative to 98.6
l/min (p  0.001). Patients with TnT 0.47 g/l were
ore than 3 times as likely to die within the first 30 days
han those with TnT 0.01 g/l (p  0.001). Compared
ith NT-proBNP 237 ng/l, the odds of 30-day mortality
teadily rose with increasing levels of NT-proBNP, partic-
larly in those 1,896 ng/l, who had nearly a 3-fold
ncrease in the risk of death (p  0.012). Strong prognostic
ssociations were also observed for heart rate and age and, to
lesser extent, histories of MI and heart failure; weight;
urrent smoker; and histories of hyperlipidemic therapy,
ercutaneous coronary intervention (PCI), and stroke.
redictors of 30-day death/MI. Among the 8 indepen-
ent predictors of 30-day death/MI, ST-segment depres-
ion and TnT made the greatest contributions. (Table 2,
ig. 1). Compared with patients without ST-segment
epression, the odds ratio of 30-day death/MI ranged from
.2 to 3 as the extent of ST-segment depression increased
p  0.001). Also, patients with TnT 0.47 g/l were over
.5 times more likely to experience the composite within 30
ays compared with those 0.01 g/l (p  0.001). Creat-
nine clearance, age, and NT-proBNP were important risk
actors, similar to the 30-day mortality model. However, the
elative contribution of NT-proBNP was attenuated com-
ays and 1 Year After Randomization
30-Day Death/MI 1-Yr Death
No Yes Survived Died
141 659 7,151 649
6–73) 72 (65–77)† 65 (56–73) 74 (68–79)†
62.4 63.1 62.7 59.3
96.8 97.0 96.8 96.5
51.5 59.2† 51.3 62.6†
35.1 36.0 34.9 37.3
21.3 27.6† 20.3 35.2†
23.1 18.5† 23.2 16.8†
45.2 54.8† 44.5 62.9†
30.6 43.7† 29.8 52.4†
7.7 14.9† 6.9 23.1†
9.8 8.6 9.8 8.8
9.3 8.2 9.1 10.5
2.4 5.3† 2.2 6.6†
8–86) 75 (66–85)† 76 (68–86) 74 (64–83)†
0–79) 71 (62–84)† 68 (60–78) 75 (64–90)†
0–100) 62 (45–83)† 79 (61–100) 56 (40–73)†
† †
34.5 19.3 34.7 16.6
27.4 20.0 27.6 18.5
27.1 34.9 27.1 35.1
4.8 13.9 4.7 15.2
6.2 11.9 5.9 14.6
.01–0.44) 0.23 (0.06–0.68)† 0.10 (0.01–0.43) 0.30 (0.06–0.84)†
23–1,702) 1,560 (529–4,288)† 635 (228–1,723) 2,926 (1,202–7,667)†
.82–9.42) 4.91 (2.15–13.0)† 3.80 (1.78–8.96) 6.97 (2.73–20.3)†
. §Confounders include left bundle branch block, paced rhythm, ventricular rhythm,
ction; NT-proBNPN-terminal pro-brain natriuretic peptide; PCI percutaneous30 D
7,
66 (5
76 (6
68 (6
78 (6
.10 (0
22 (2
.91 (1
vived)ared with the mortality models (Fig. 1). Unlike the
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Value-Added Risk Stratification in ACS September 5, 2006:939–47ortality model, heart rate was not a significant indepen-
ent predictor of 30-day death/MI.
redictors of 1-year death. ST-segment depression was
he strongest contributor to the model predicting 1-year
ortality, similar to the 30-day mortality model (Table 2,
ig. 1). A marked gradient in risk relative to ST-segment
epression was observed, even after baseline adjustment:
atients with 2 mm were 2.4 times more likely to die
ithin the first year compared with those without ST-
egment depression (p  0.001). Other important predic-
ors included creatinine clearance, NT-proBNP, age, heart
ate, and TnT. For instance, patients who had 58 ml/min
reatinine clearance were nearly 4 times more likely to die
ithin the first year compared with 98.6 ml/min. In
ontrast to 30-day mortality, CRP, diabetes, and prior
ngina were significant prognostic factors, whereas past use
f hyperlipidemic therapy and PCI were no longer signifi-
able 2. Adjusted OR and 95% CI of Baseline Characteristics P
30-Day Mortality
Adjusted OR
(95% CI) p Value
Chi-
Square
ge, yrs 1.03 (1.01–1.05) 0.001 10.7
urrent smoker 1.60 (1.1–2.3) 0.008 6.7
iabetes mellitus
istory of hyperlipidemic therapy 1.41 (1.1–1.8) 0.009 6.6
istory of angina
istory of MI 1.46 (1.1–1.8) 0.005 7.9
istory of heart failure 1.56 (1.1–2.1) 0.006 7.1
istory of stroke 1.80 (1.1–3.0) 0.021 4.8
o history of PCI 1.70 (1.05–2.76) 0.034 5.1
o history of CABG
eart rate, beats/min 1.02 (1.0–1.02) 0.001 17.1
ody weight, kg 1.01 (1.0–1.03) 0.009 6.8
reatinine clearance, ml/min
98.6 1 0.001 39.8
76.9–98.6 2.17 (1.1–4.1)
58.4–76.9 3.61 (1.9–6.8)
58.4 5.39 (1.1–4.1)
T-segment depression, mm
No 1 0.001 45.1
0.5 1.10 (0.7–1.7)
1.0–1.5 1.73 (1.2–2.5)
2 3.73 (2.4–5.8)
Confounders 2.42 (1.5–3.8)
roponin-T, ug/l
0.01 1 0.001 33.7
0.01–0.12 2.06 (1.2–3.4)
0.12–0.47 2.09 (1.2–3.5)
0.47 3.54 (2.1–5.8)
T-proBNP, ng/l
237 1 0.012 13.7
237–669 1.60 (0.8–3.2)
669–1,896 2.00 (1.0–3.9)
1,896 2.72 (1.4–5.3)
RP, mg/l
1.84
1.84–3.96
3.96–9.62
9.62
I  confidence interval; OR  odds ratio; other abbreviations as in Table 1.ant factors to long-term prognosis. There was also a dignificant interaction between NT-proBNP and age (p 
.006). In 30-day survivors, the risk profile changed to some
xtent (Appendix 2, Table A2.1). Whereas TnT was no
onger a significant factor, 30-day post-randomization PCI
educed the likelihood of death by 50% (p  0.001).
odel performance. The Hosmer-Lemeshow goodness-
f-fit test statistic indicated adequate fit of all models
30-day mortality: chi-square  4.72 [p  0.787]; 30-day
eath/MI: chi-square  11.84 [p  0.158]; 1-year mortal-
ty: chi-square  5.72 [p  0.679]), and calibration was
xcellent (Fig. 2). The c-index was 0.83 for the 30-day
ortality model, which reflected excellent discriminatory
ower. The level of over-optimism determined by boot-
trapping was 0.01, which reduced the c-indexadjusted to
.82. The model predicting 1-year mortality had compara-
le discriminatory power of c-indexadjusted  0.81 (over-
ptimism  0.01), whereas it was lower for 30-day
ting 30-Day Mortality, 30-Day Death/MI, and 1-Year Mortality
30-Day Death/MI 1-Yr Mortality
justed OR
(95% CI) p Value
Chi-
Square
Adjusted OR
(95% CI) p Value
Chi-
Square
2 (1.01–1.03) 0.001 10.9 1.04 (1.02–1.05) 0.001 29.6
1.70 (1.3–2.2) 0.001 15.9
1.38 (1.1–1.7) 0.001 10.7
1.45 (1.2–1.8) 0.001 14.7
9 (1.16–1.65) 0.001 10.6 1.59 (1.3–1.9) 0.001 23.4
1.64 (1.3–2.1) 0.001 16.2
8 (1.07–2.34) 0.023 4.5 1.67 (1.1–2.5) 0.010 6.3
5 (1.14–2.11) 0.006 8.0
1.01 (1.0–1.02) 0.001 24.3
1 (1.01–1.02) 0.001 12.0 1.01 (1.0–1.01) 0.007 7.3
1 0.001 25.0 1 0.001 42.9
6 (0.99–1.86) 1.89 (1.3–2.8)
1 (1.22–2.39) 2.54 (1.7–3.8)
9 (1.64–3.49) 3.85 (2.5–6.02)
1 0.001 69.7 1 0.001 41.0
8 (0.91–1.53) 1.05 (0.8–1.4)
4 (1.38–2.21) 1.37 (1.1–1.8)
4 (2.31–4.26) 2.42 (1.7–3.4)
7 (1.66–3.11) 2.03 (1.5–2.8)
1 0.001 42.2 1 0.001 23.5
0 (1.61–3.01) 1.31 (0.95–1.8)
8 (1.74–3.26) 1.60 (1.2–2.2)
2 (1.83–3.46) 1.99 (1.5–2.7)
1 0.041 10.3 1 0.001 30.0
6 (1.04–2.06) 1.33 (0.9–2.1)
0 (0.92–1.83) 1.80 (1.2–2.8)
6 (1.17–2.36) 2.58 (1.7–4.0)
1 0.05 8.8
1.10 (0.8–1.5)
1.06 (0.8–1.4)
1.38 (1.0–1.8)redic
Ad
1.0
1.3
1.5
1.5
1.0
1.3
1.7
2.3
1.1
1.7
3.1
2.2
2.2
2.3
2.5
1.4
1.3
1.6eath/MI (0.72 [over-optimism  0.01]).
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September 5, 2006:939–47 Value-Added Risk Stratification in ACSncremental value of novel risk factors. The incremental
alue of quantitative ST-segment depression and these
iomarkers over “traditional” patient characteristics (e.g.,
ge, comorbidities, history of cardiovascular disease, heart
ate) was assessed with 2 approaches. First, the relative
ontribution of each independent predictor in the model
as estimated (Fig. 1). Second, as each of these novel risk
actors was added to the model of traditional baseline
haracteristics, a noticeable increase in the c-indexadjusted
as observed (Fig. 3).
implified risk scores. As shown in Figure 4, the 5-factor
isk score ranged from 0 in patients with no risk factors to
1 in those with all (and the most severe degree) of the risk
actors for 30-day mortality, from 0 to 39 for 30-day
eath/MI, and from 0 to 48 for 1-year mortality. The accom-
anying nomogram translates the risk score into the likeli-
ood of the outcome. The discriminatory power of the risk
cores was slightly attenuated but remained reasonably
trong (c-indexadjusted  0.78, 0.67, and 0.77, respectively).
ISCUSSION
his large study of contemporary NSTE-ACS patients
ighlights the striking prognostic value of quantitative
T-segment depression even in the context of an expanded
iomarker profile including creatinine clearance, NT-
roBNP, TnT, and CRP as well as other more traditional
aseline risk factors such as creatinine clearance and age.
Electrocardiography has long been an essential clinical
ool in the evaluation of ACS as it is inexpensive, readily
vailable, and non-invasive. Numerous studies on the basis
f clinical trial and registry samples have also demonstrated
igure 1. Relative contribution of significant, independent factors to the p
eath. Creat. Cl. creatinine clearance; CRP C-reactive protein; Curr. S
x CABG  history of coronary artery bypass graft; Hx CHF  history
yperlipidemic therapy; Hx PCI  history of percutaneous coronary inte
atriuretic peptide; ST-dep  ST-segment depression; TnT  troponinhat ST-segment depression on the admission ECG is tighly influential on short- and long-term outcomes
6,15,16). Although the binary indicator (i.e., presence
s. absence of ST-segment depression) is often used in
isk stratification, an increasing body of evidence, includ-
ng this study, has demonstrated that quantitative ST-
egment depression is a substantial refinement (7,8). The
ARAGON-A (Platelet IIb/IIIa Antagonism for the Re-
uction of Acute Global Organization Network) investiga-
ors (7) noted a steady increase in 30-day and 1-year
ortality as the extent of ST-segment depression rose
30-day mortality: 0.7% [no ST-segment depression], 2.8%
1-mm], and 6.3% [2-mm ST-segment depression];
-year mortality: 2.0%, 7.8%, and 13.4%, respectively).
fter baseline adjustment, ST-segment depression made
he highest relative contribution to the prediction of 1-year
ortality, which was similarly observed in this study.
The quantitative collection of indicators of renal function,
yocardial necrosis, hemodynamic stress, and inflammation
ffered a unique opportunity to explore the pathophysiology
f ACS. Abnormal renal function is a well-documented
redictor of morbidity and mortality in a wide variety of
atients (17). In concert with other ACS studies, lower
evels of creatinine clearance were significantly associated
ith poorer short- and long-term prognosis, even though
atients with advanced renal dysfunction were excluded
rom this trial (9). Impaired renal function might also alter
he prognostic value of other serum biomarkers, because
heir clearance might be inhibited; however, previously
ublished findings dispel this concern (11,18).
In the past, creatine kinase-MB was the reference stan-
ard in MI diagnosis, but troponins have replaced creatine
inase-MB with improved sensitivity and specificity (13). In
ion of 30-day death, 30-day death/myocardial infarction (MI), and 1-year
 current smoker; HR heart rate; Hx Ang history of angina pectoris;
ngestive heart failure; Hx MI  history of MI; Hx lipidRx  history of
ion; Hx strk  history of stroke; NT-proBNP  N-terminal pro-brain
gt  weight.redict
mok.
of cohe current study, TnT was ranked second and third among
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espectively, which reflects its role as a highly sensitive
arker of myocardial necrosis in the acute phase. Although
nT remained a significant predictor of 1-year mortality (in
ll-comers), its influence declined over time after the index
oronary event.
Elevated levels of BNP have been linked with left
entricular dysfunction and poorer prognosis in patients
ith heart failure and other associated disorders. Recently,
hese observations have been extended to ACS patients in
hom elevated BNP levels also might be the result of
ransient ischemia (19–21). As demonstrated previously,
ncreasing quartiles of NT-proBNP were strongly related to
n increase in the odds of 30-day and 1-year mortality but
ot of 30-day MI, after multivariable adjustment (21).
lthough this relationship remained robust in the current
tudy, it was no longer the top contributor of prognostic
nformation after introducing the extent of ST-segment
epression.
The role of inflammation in the pathophysiology of ACS
s increasingly important, with CRP as one of the best
ecognized markers. Although once thought to have a
assive role in vascular inflammation, CRP might be an
ctive contributor to atherogenesis, as suggested by recent
vidence (22). Similar to the current study, others observed
hat the prognostic impact of elevated CRP was not evident
arly after the coronary event but emerged later as an index
f the ongoing evolution of coronary artery disease (23–25).
Classical risk factors such as age and heart rate played a
ignificant role in risk prediction; however, compared with
reviously published risk models, these factors lost consid-
rable prognostic value in the current study with the
nclusion of quantitative ST-segment depression and bi-
markers (1,2,26). Heart rate was not an independent
redictor of 30-day death/MI, a finding similar to those of
ther studies, (2).
linical implications. Whether risk stratification that de-
nes the optimal management strategy should be driven by
oninvasive determinants of ischemia or knowledge of the
oronary anatomy remains controversial. Although there is
eneral consensus that patients at highest baseline risk tend
o benefit most from early invasive therapy, others have
rgued that despite risk, invasive angiography and/or revas-
ularization should become the standard of care in virtually
ll such patients. Higher rates of early invasive treatment,
owever, do not necessarily translate into improved out-
omes in all patients, especially in those without ST-
egment changes (27–29). International practice patterns
evealed that the use of angiography and angioplasty in
STE-ACS patients was inversely related to the extent of
T-segment depression (30). Thus, improved risk assess-
ent as proposed in the current study would better identify
atients at increased risk, in whom coronary intervention
hould be considered, and its implementation might result
n the increased efficiency of care. It seems clear that
pplication of this approach depends, to some extent, onigure 2. Calibration of risk models: (A) 30-day death; (B) 30-day
eath/myocardial infarction (MI); (C) 1-year death. Dots represent decileshat risk one aims to predict and when. As evident in
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nced by ST-segment depression, renal function, cardiac
roponin, and NT-proBNP in addition to traditional risk
actors. The relative contribution of ST-segment depression
nd troponin is actually enhanced as it relates to 30-day
eath/MI. By 1 year some repositioning occurs such that
ge, diabetes, prior angina, and CRP appear as factors
ssociated with mortality: whereas the influence of ST-
egment depression remains strong, NT-proBNP is
trengthened, and troponin is attenuated.
Identifying appropriate treatment strategies might be
acilitated through the use of simplified risk models in
linical practice. Several user-friendly risk scores have been
eveloped from clinical trial and registry populations, such
s the Thrombolysis In Myocardial Infarction (TIMI) risk
core in NSTE-ACS and the recently published risk score
rom the GRACE (Global Registry of Acute Coronary
vents) registry (3,4). However, there are notable limita-
ions. Although the TIMI risk score contains few factors, its
igure 3. Increase in adjusted C-index as biomarkers and quantitative ST-
nd 1-year death (closed dots) and (B) 30-day death or MI (closed diamiscriminatory power is modest (c-index  0.65), which timits its clinical application. And although the GRACE
egistry risk score extends beyond the TIMI risk score to
nclude serum creatinine, heart rate, and systolic blood
ressure, it is lacking quantitative ST-segment depression,
T-proBNP, and CRP, which were shown to have signif-
cant prognostic value in the current study and other studies.
Some limitations of our study should be addressed. First,
aseline systolic blood pressure was not available and could
ave influenced our findings. However, this seems unlikely.
n ad hoc analysis of the PURSUIT (Platelet Glycoprotein
Ib/IIIa in Unstable Angina: Receptor Suppression Using
ntegrilin Therapy) 30-day death model revealed that if
ystolic blood pressure was not included, the top 5 predic-
ors (as measured by percent Sigma chi-square) to the
odel—heart rate(interaction with AMI/UA), age, rales, ST-
egment depression (yes/no), and region of enrollment—
ssentially remained unchanged from the model that in-
luded systolic blood pressure (2). Notably, if one of the top
ndicators, such as heart rate, was not included in the model,
ent depression are added to the models predicting (A) 30-day (open dots)
). Abbreviations as in Figure 1.segmhe structure of the overall model changed significantly.
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CS population might be in question. According to the
rotocol, coronary angiography was restricted at least 12 h
fter the completion of the study drug infusion. Although
his might not be routine procedure in many tertiary
acilities, it likely is representative of the sizeable proportion
f the overall ACS population who do not present directly
o these facilities. And finally, the external validation of
hese risk models was not provided. To our knowledge,
o other clinical trial or population-based cohort pos-
esses the requisite ECG and/or biomarker data required
or this task. Validation of clinically meaningful cut
oints will also be important. Future investigations
hould incorporate these indicators into their design to
chieve this.
In conclusion, the degree of ST-segment depression was
he highest contributor to the prediction of 30-day and
-year mortality and 30-day death/MI in a contemporary
ample of 7,800 NSTE-ACS patients. Creatinine clearance,
nT, and NT-proBNP also were significant independent
rognostic indicators of adverse outcomes, whereas CRP
as only significant in the long-term prediction. The
urrent study provides novel contemporary insights into the
igure 4. Simplified risk score and nomogram to estimate risk of mortalit
nfarction (MI) at 30 days (solid x’s).isk stratification of NSTE-ACS patients, which might be wf particular value in identifying strategies for risk reduction
nd the planning of future studies.
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PPENDIX
or an independent analysis of the relative prognostic power
f TnT over creatine kinase-MB as the preferred marker of
yocardial damage and adjusted odds ratios and 95%
onfidence intervals of baseline characteristics in predicting
-year mortality in 30-day survivors, please see the online
ersion of this article.
